Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
A proposed sale for Director and Officer Daniel O'Day involves 112,429 shares of Gilead Sciences, Inc. common stock, with a stated aggregate market value of $18,828,484.63 and an approximate sale date of November 4, 2026. Morgan Stanley Smith Barney LLC is named as broker. The shares are to be received through stock-option exercises over the next three months, and acquisition and payment dates are tied to exercise/sale dates.
Daniel Patrick O'Day, Gilead Sciences, Inc.'s Chairman & CEO and a director, reported six sales totaling 30,881 shares on October 30 and November 2, 2026, under a Rule 10b5-1 trading plan adopted February 25, 2026.
On October 30, he exercised non-qualified options for 15,881 shares at a $72.34 exercise price and sold those shares at the reported price of $175.2456 per share. The option record reports 240,739 options following the exercise.
Gilead Sciences, Inc. officer and director Daniel O'Day reported a proposed sale of 45,881 common shares, with an approximate sale date of October 30, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. The stated aggregate market value is $7,598,352.41. His reported 10b5-1 sales in the preceding three months included 15,000 shares on October 1, 2026, for $2,218,507.50; 15,000 shares on September 1, 2026, for $2,229,592.50; and 15,000 shares on August 3, 2026, for $1,954,693.80.
Gilead Sciences, Inc. (GILD) reported third-quarter 2026 revenue of $8.3 billion, up 7% year over year, while net income was $2.429 billion, down 20%. For the nine months ended September 30, 2026, revenue rose 7% to $23.063 billion, but Gilead recorded a $6.045 billion net loss, versus $6.327 billion in net income a year earlier. Gilead attributed the loss primarily to $11.307 billion of acquired in-process research and development expenses and a $1.75 billion impairment charge tied to an NSCLC research asset.
Nine-month HIV product sales increased 14% to $17.0 billion. Gilead completed acquisitions of Arcellx for approximately $6.4 billion and Tubulis for approximately $3.2 billion in cash consideration, net of cash acquired. In October 2026, it entered a definitive agreement to acquire PepStar’s oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion in upfront cash consideration, subject to customary adjustments and payable at closing; the transaction is expected to close in the fourth quarter of 2026, subject to certain conditions.
Nine-month operating cash flow was $11.152 billion, compared with $6.692 billion a year earlier. FDA approved Bixlenvo and granted accelerated approval to Hepcludex; the Medicare Maximum Fair Price for Biktarvy is set to affect its revenue beginning January 1, 2028.
Gilead Sciences, Inc. reported third-quarter 2026 total revenue of $8.3 billion, up 7% year over year, and product sales of $8.289 billion, up 13%. Product sales excluding Veklury increased 16% to $8.203 billion; HIV sales rose 18% to $6.249 billion. GAAP diluted EPS was $1.94 versus $2.43 a year earlier, while non-GAAP diluted EPS was $2.55 versus $2.47.
Operating cash flow was $5.035 billion, compared with $4.109 billion. Cash, cash equivalents and marketable debt securities were $6.437 billion as of September 30, 2026, versus $10.605 billion as of December 31, 2025. Updated 2026 guidance calls for product sales of $31.0 billion–$31.3 billion, versus $30.1 billion–$30.4 billion previously, and GAAP diluted loss per share of $(4.40)–$(4.05), versus $(3.75)–$(3.40).
The FDA approved Bixlenvo as a single-tablet HIV regimen for adults virologically suppressed on a stable antiretroviral regimen with no known or suspected resistance to bictegravir or lenacapavir. The board declared a $0.82-per-share fourth-quarter dividend, payable December 30, 2026.
Gilead Sciences, Inc. (GILD) Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock on October 15, 2026, at $156.22 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 29, 2024. Dickinson reported direct holdings of 161,096 shares after the transaction.
Gilead Sciences, Inc. (GILD) Chief Comm & Corp Aff Officer Johanna Mercier reported a sale of 3,000 shares of common stock at $156.22 per share on October 15, 2026. The sale was made under a Rule 10b5-1 trading plan adopted on February 20, 2025; her reported direct holdings after the transaction were 113,684 shares.
Gilead Sciences officer Johanna Mercier reported a proposed sale of 3,000 common shares with an aggregate market value of $468,660. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ as the market for the proposed sale. The shares are identified as performance shares acquired from the issuer on February 4, 2025.
Gilead Sciences, Inc. officer Andrew Dickinson gave notice of a proposed sale of 3,000 common shares, with an aggregate market value of $468,660, through Morgan Stanley Smith Barney LLC; the notice lists October 15, 2026, as the approximate sale date and Nasdaq as the exchange. It identifies 3,000 performance shares acquired from the issuer on January 31, 2024. It also lists two sales during the prior three months: 3,000 shares on September 15, 2026, for $435,870 and 3,000 shares on August 17, 2026, for $415,080.
Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported selling 15,000 shares of common stock in two direct transactions on October 1, 2026: 12,000 shares at a reported $147.7190 per share and 3,000 shares at $148.6265 per share. The applicable sale-price ranges were $147.21 to $148.205 and $148.23 to $149.13, respectively.